CVS Health (CVS) IV increases into EPS and outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq rise in choppy trading as tech steadies, Micron results in focus
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
CVS Health (CVS) PT Lowered to $68 at Baird
February 21, 2019 8:35 AM ESTBaird analyst Eric Coldwell lowered the price target on CVS Health (NYSE: CVS) to $68.00 (from $86.00) while maintaining a Neutral rating. Mid-$7 EPS in 2020 looks like a best-case scenario. Derivative reads scattered throughout CVS update, most of them unfavorable for peers/vendors.
CVS is... More
